ArticleJournal of clinical medicine2024
Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study.
Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review.European urology open science · 2026Review
- Apalutamide-induced prostate-specific antigen response and its association with clinical outcomes in metastatic castration sensitive prostate cancer (Review).Molecular and clinical oncology · 2026Review
- Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- PSA Response as a Prognostic Marker in Metastatic Hormone-sensitive Prostate Cancer: Comparison with Tumor Volume (CHAARTED).European urology open science · 2026Article
- Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancer.Therapeutic advances in medical oncology · 2026Article
- Prognostic Significance of Ultralow (UL) Prostate-Specific Antigen (PSA) in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Single Institution and Tertiary Cancer Center Experience.Medicina (Kaunas, Lithuania) · 2025Article
- Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate Cancer.European urology open science · 2025Article
- Real-world effectiveness of rezvilutamide plus androgen deprivation therapy in patients with low-volume, metastatic hormone-sensitive prostate cancer: a retrospective multicenter study.Translational andrology and urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.